ZyVersa Therapeutics, Inc. (ZVSA)
OTCMKTS · Delayed Price · Currency is USD
0.1134
+0.0144 (14.55%)
At close: Sep 18, 2026
ZyVersa Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Selling, General & Admin | 5.09 | 5.73 | 6.42 | 6.52 | 6.93 | 7.36 | 7.71 | 8.11 | 9.99 | 11.21 | 13.19 | 12.03 | 9.26 | 8.03 | 5.67 | 6.32 | 6.51 | 5.58 | 5.36 |
Research & Development | 0.91 | 1.11 | 1.16 | 1.23 | 1.53 | 1.78 | 1.92 | 2.15 | 2.66 | 3.21 | 4.64 | 6.3 | 5.8 | 5.81 | 4.75 | 2.83 | 2.6 | 2.12 | 6.47 |
Operating Expenses | 6 | 6.84 | 7.58 | 7.74 | 8.45 | 9.14 | 9.63 | 10.26 | 12.66 | 14.42 | 17.83 | 18.32 | 15.06 | 13.83 | 10.42 | 9.14 | 9.11 | 7.7 | 11.83 |
Operating Income | -6 | -6.84 | -7.58 | -7.74 | -8.45 | -9.14 | -9.63 | -10.26 | -12.66 | -14.42 | -17.83 | -18.32 | -15.06 | -13.83 | -10.42 | -9.14 | -9.11 | -7.7 | -11.83 |
Interest Expense | -0.53 | -0.51 | -0.52 | -0.52 | -0.39 | -0.27 | -0.13 | -0 | -0 | - | -0.05 | -0.12 | -0.26 | -0.43 | -0.58 | -0.74 | -0.82 | -0.82 | -0.52 |
Interest & Investment Income | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | - | - | - | - | - |
Other Non Operating Income (Expenses) | -0.02 | - | 0.2 | -0.03 | 0.01 | - | - | - | - | - | -0.19 | -0.41 | -0.39 | -0.61 | -0.41 | 0.07 | 0.02 | 0.23 | -0.33 |
EBT Excluding Unusual Items | -6.55 | -7.36 | -7.9 | -8.29 | -8.84 | -9.41 | -9.76 | -10.26 | -12.66 | -14.42 | -18.07 | -18.86 | -15.71 | -14.87 | -11.41 | -9.82 | -9.91 | -8.3 | -12.68 |
Impairment of Goodwill | - | - | - | - | - | - | - | - | -11.9 | -11.9 | -11.9 | -11.9 | - | - | - | - | - | - | - |
Other Unusual Items | -0.14 | 0.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.21 | 0.21 | 0.21 | - |
Pretax Income | -25.34 | -25.8 | -26.55 | -8.29 | -8.84 | -9.41 | -21.92 | -22.42 | -105.99 | -107.75 | -99.24 | -100.03 | -15.71 | -14.87 | -11.41 | -9.6 | -9.69 | -8.08 | -12.68 |
Income Tax Expense | -0.85 | -0.85 | -0.85 | -0 | 0.01 | 0.01 | -0.59 | -0.59 | -8.41 | -9.46 | -9.6 | -9.6 | -1.79 | -0.75 | - | - | - | - | - |
Net Income | -24.49 | -24.95 | -25.7 | -8.29 | -8.84 | -9.41 | -21.33 | -21.83 | -97.58 | -98.3 | -89.64 | -90.43 | -13.92 | -14.12 | -11.41 | -9.6 | -9.69 | -8.08 | -12.68 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | - | - | 0.03 | 7.95 | 7.95 | -2.07 | 7.58 | - | - | 10.02 | 0.33 | - | - | - |
Net Income to Common | -24.49 | -24.95 | -25.7 | -8.29 | -8.84 | -9.41 | -21.33 | -21.86 | -105.53 | -106.25 | -87.57 | -98.01 | -13.92 | -14.12 | -21.43 | -9.93 | -9.69 | -8.08 | -12.68 |
Net Income Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding (Basic) | 7 | 6 | 4 | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 23 | 23 | 0 | 23 | 0 | 0 | 0 | 2 | 0 |
Shares Outstanding (Diluted) | 7 | 6 | 4 | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 23 | 23 | 0 | 23 | 0 | 0 | 0 | 2 | 0 |
Shares Change (YoY) | 316.62% | 437.28% | 564.62% | 516.02% | 601.10% | 1038.49% | -97.10% | -98.07% | 350.31% | -99.58% | 33105.67% | 33095.22% | -20.60% | 849.06% | - | - | - | 3478.59% | - |
EPS (Basic) | -3.40 | -4.18 | -5.81 | -3.04 | -5.11 | -8.48 | -32.03 | -49.37 | -427.45 | -1089.70 | -3.82 | -4.28 | -253.87 | -0.62 | -310.36 | -143.85 | -140.37 | -3.35 | -187.81 |
EPS (Diluted) | -3.40 | -4.18 | -5.81 | -3.04 | -5.11 | -8.48 | -32.03 | -49.37 | -427.45 | -1089.70 | -3.82 | -4.28 | -253.87 | -0.62 | -310.36 | -143.85 | -140.37 | -3.35 | -187.81 |
EPS Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Additional Metrics
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
EBITDA | - | -6.84 | -7.57 | -7.74 | -8.45 | -9.13 | -9.62 | -10.25 | -12.64 | -14.41 | -17.82 | -18.31 | -15.05 | -13.82 | -10.41 | -9.13 | -9.1 | -7.69 | -11.82 |
D&A For EBITDA | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
EBIT | -6 | -6.84 | -7.58 | -7.74 | -8.45 | -9.14 | -9.63 | -10.26 | -12.66 | -14.42 | -17.83 | -18.32 | -15.06 | -13.83 | -10.42 | -9.14 | -9.11 | -7.7 | -11.83 |